Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Hamilton Health Sciences: Clinical Trials & FDA Approval Profile

Hamilton Health Sciences (Global / Institutional) sponsors 22 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (6 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)18.2%
Median Closed Enrollment vs National (145 pts)101 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Hamilton Health Sciences
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)22
Active Pipeline (Recruiting Now)9 (6)
Completed vs Stopped Early4 / 4 (18.2%)
Median Closed Actual Enrollment101 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Hamilton Health Sciences
Hospital Research SiteLocationShared Protocols
London Health Sciences CentreLondon, Ontario4
Sunnybrook Health Sciences CentreToronto, Ontario2
McGill University Health CentreMontreal, Quebec2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Hamilton Health Sciences
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06174220Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic CardiomyopathyPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Hamilton Health Sciences Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI